Small Cell Lung Cancer (SCLC) FFPE
Small Cell Lung Cancer
Key Facts
About The MT Group
The MT Group is a specialized biospecimen CRO with over 20 years of experience, providing critical research materials and services to the life sciences industry. The company differentiates itself through its 'MT Level' metadata, offering deeply annotated biospecimens linked to comprehensive clinical data, which is essential for robust translational and diagnostic research. Its business model is built on custom collection projects, a vast site network, and a partnership-oriented approach that drives significant repeat business from global biopharma and diagnostic clients. While privately held and service-based, it plays a foundational role in the R&D value chain by addressing the pre-analytical variable challenges in assay and therapeutic development.
View full company profileTherapeutic Areas
Other Small Cell Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| IMX101 | Imunexus Therapeutics | Preclinical |
| LNTH-2503 | Lantheus Medical Imaging | Phase 1 |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Discovery Program | Disco Pharmaceuticals | Discovery |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase III |
| SCLC Program | Arcellx | Discovery |
| APG-1252 (Pelcitoclax) | Ascentage Pharma Group | Phase 1/2 |
| zocilurtatug pelitecan (ZL-1310) | Zai Lab | Phase 3 |